# A Bioequivalence Study of Capecitabine Tablets

> **NCT01846650** · PHASE1 · COMPLETED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 36 (actual)

## Conditions studied

- Metastatic Breast Cancer or Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Capecitabine tablets
- **DRUG:** XELODA

## Key facts

- **NCT ID:** NCT01846650
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2013-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01846650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01846650, "A Bioequivalence Study of Capecitabine Tablets". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01846650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*